Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Aclidinium Bromide : Clinical Benefit in Patients with Moderate to Severe COPD. / Ulrik, Charlotte Suppli.

I: The Open Respiratory Medicine Journal, Bind 6, 2012, s. 150-4.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ulrik, CS 2012, 'Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD', The Open Respiratory Medicine Journal, bind 6, s. 150-4. https://doi.org/10.2174/1874306401206010150

APA

Ulrik, C. S. (2012). Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD. The Open Respiratory Medicine Journal, 6, 150-4. https://doi.org/10.2174/1874306401206010150

Vancouver

Ulrik CS. Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD. The Open Respiratory Medicine Journal. 2012;6:150-4. https://doi.org/10.2174/1874306401206010150

Author

Ulrik, Charlotte Suppli. / Aclidinium Bromide : Clinical Benefit in Patients with Moderate to Severe COPD. I: The Open Respiratory Medicine Journal. 2012 ; Bind 6. s. 150-4.

Bibtex

@article{3603ff7253aa4a778a706ffc7a4e8898,
title = "Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD",
abstract = "Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.",
author = "Ulrik, {Charlotte Suppli}",
year = "2012",
doi = "10.2174/1874306401206010150",
language = "English",
volume = "6",
pages = "150--4",
journal = "The Open Respiratory Medicine Journal",
issn = "1874-3064",
publisher = "Bentham Open",

}

RIS

TY - JOUR

T1 - Aclidinium Bromide

T2 - Clinical Benefit in Patients with Moderate to Severe COPD

AU - Ulrik, Charlotte Suppli

PY - 2012

Y1 - 2012

N2 - Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.

AB - Long-acting bronchodilators are the mainstay of pharmacological treatment for patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD.

U2 - 10.2174/1874306401206010150

DO - 10.2174/1874306401206010150

M3 - Journal article

C2 - 23264836

VL - 6

SP - 150

EP - 154

JO - The Open Respiratory Medicine Journal

JF - The Open Respiratory Medicine Journal

SN - 1874-3064

ER -

ID: 48598043